{
    "2018-03-26": [
        [
            {
                "time": "2018-03-15",
                "original_text": "U.S. jury orders AbbVie to pay $3 mln in AndroGel retrial",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "AndroGel",
                        "jury",
                        "pay"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "The Biggest Movers: Microsoft Shines; AbbVie Slumps",
                "features": {
                    "keywords": [
                        "Microsoft",
                        "AbbVie",
                        "Biggest Movers",
                        "Slumps"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Monday's ETF with Unusual Volume: XMX",
                "features": {
                    "keywords": [
                        "ETF",
                        "Unusual Volume",
                        "XMX"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Exploring Xencor’s Cash Flows",
                "features": {
                    "keywords": [
                        "Xencor",
                        "Cash Flows"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "Analysts’ Recommendations for Xencor and Its Peers in March",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "Xencor",
                        "Peers"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-15",
                "original_text": "The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer",
                "features": {
                    "keywords": [
                        "Zacks",
                        "Analyst Blog",
                        "AbbVie",
                        "J&J",
                        "Heron Therapeutics",
                        "Roche",
                        "Pfizer"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}